Patents Examined by Merrell C. Cashion, Jr.
  • Glucagon analogs with ASP.sup.9 replacements or deletions
    Patent number: 5143902
    Abstract: Glucagon analogs characterized principally by the removal of the 9-aspartic acid residue or its replacement with an amino acid residue other than an L- dibasic amino acid containing up to five carbon atoms with or without a histidine at the amino terminal are useful adjuncts to insulin therapy.
    Type: Grant
    Filed: December 16, 1991
    Date of Patent: September 1, 1992
    Assignee: The Rockefeller University
    Inventors: Robert B. Merrifield, Cecilia G. Unson
  • Synthetic vasoactive intestinal peptide analogs
    Patent number: 5141924
    Abstract: Vasoactive intestinal peptide analogs containing substitutions of appropriately selected amino acids at specific positions of the VIP molecule.
    Type: Grant
    Filed: June 30, 1989
    Date of Patent: August 25, 1992
    Assignee: Hoffmann-La Roche, Inc.
    Inventor: David R. Bolin
  • Methods for the treatment of retroviral infections
    Patent number: 5141923
    Abstract: The present invention provides novel methods for the treatment of retroviral infection, particularly HIV disease. According to the present invention, human HIV infected hosts were selected who had been on a stable dose of an anti-retroviral agent, such as zidovudine, for up to two years prior to administration of the ribosomal inhibiting protein trichosanthin, and who had failed anti-retroviral therapy, as manifest by decrease in CD4+ cells on at least two serial measurements, or loss of over 50 CD4+ cells/mm.sup.3 /year. These patients remained on the same dose of anti-retroviral agent (AZT or ddI) and received trichosanthin, 1.2 mg weekly, then monthly. A significant number of patients demonstrated improved CD4+ cell counts following administration of trichosanthin as compared to CD4+ cell counts prior to adminstration of the drug.
    Type: Grant
    Filed: December 31, 1990
    Date of Patent: August 25, 1992
    Assignee: Immunology, Inc., a California corporation
    Inventors: Vera K. Byers, Alan S. Levin
  • Dielectric structures having embedded gap filling RIE etch stop polymeric materials of high thermal stability
    Patent number: 5141817
    Abstract: Structures containing a dielectric material having a polymeric reactive ion etch barrier embedded therein. The preferred dielectric materials are polymers, preferably polyimide materials. The RIE etch barrier is a copolymer having an aromatic component having high thermal stability and having a cross-linking component selected from metallacyclobutane, metallabutene and vinyl groups. The etch barrier is deposited as a solvent free liquid which can fill gaps between the dielectric material and electrical conductors embedded therein. The liquid polymer is cured to a solid insoluble state. The structures with electrical conductors embedded therein are useful for electronic applications.
    Type: Grant
    Filed: June 13, 1989
    Date of Patent: August 25, 1992
    Assignee: International Business Machines Corporation
    Inventors: Edward D. Babich, Michael Hatzakis, Richard P. McGouey, Sharon L. Nunes, Jurij R. Paraszczak, Jane M. Shaw
  • Octapeptide LHRH antagonists
    Patent number: 5140009
    Abstract: The present invention relates to novel LHRH analogs. The LHRH analogs include "pseudo" hexapeptide, heptapeptide, octapeptide and nonapeptide analogs of LHRH, wherein all or some of the amino acids, 1, 2 and 3 have been eliminated and the remaining (2-9), (2-10), (3-9), (3-10), (4-9) or (4-10) peptide is linked to various carboxylic acids which take the place of amino acids 1, 2 or 3 in LHRH.
    Type: Grant
    Filed: July 10, 1990
    Date of Patent: August 18, 1992
    Assignee: Tap Pharmaceuticals, Inc.
    Inventors: Fortuna Haviv, Jonathan Greer, Christopher A. Palabrica, Timothy D. Fitzpatrick
  • Stabilized aqueous formulations of thymopentin
    Patent number: 5140010
    Abstract: The present invention provides a method for preparing aqueous formulations of thymopentin, which method permits the peptide to retain its biological activity during storage at room temperature.
    Type: Grant
    Filed: March 6, 1991
    Date of Patent: August 18, 1992
    Assignee: Immunobiology Research Institute
    Inventors: Gideon Goldstein, Tapan Audhya
  • Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase
    Patent number: 5140102
    Abstract: A novel pentadecapeptide is disclosed which is useful for the control of intestinal fluid absorption and that has the following amino acid sequence ##STR1##
    Type: Grant
    Filed: September 23, 1991
    Date of Patent: August 18, 1992
    Assignee: Monsanto Company
    Inventor: Mark G. Currie
  • Pesticidal formulations
    Patent number: 5139773
    Abstract: Mixtures of different pesticides, in emulsion and suspension form respectively, are stabilized by incorporation in the mixture of the emulsion and suspension a dispersant capable of being strongly adsorbed onto the particles of the pesticide in suspension form, such a dispersant being a block of graft copolymer as described in UK Patent Specification Number 2026341-A and/or 1196248.
    Type: Grant
    Filed: April 26, 1988
    Date of Patent: August 18, 1992
    Assignee: Imperial Chemical Industries PLC
    Inventor: Tharwat F. Tadros
  • Cyclopeptide derivatives usable as selective inhibitors with respect to proteases with active serine
    Patent number: 5138035
    Abstract: The invention relates to cyclopeptide derivative usable as protease inhibitors and complying with formula: ##STR1## in which R.sup.1 is a halogen atom, e.g. bromine or a radical such as S.sup.+ R.sub.2.sup.4 X.sub.1/v.sup.v-, R.sup.2 is a hydrogen atom, an alkyl radical, a halogen atom or other groups, R.sup.3 is NH, O or S, Z comprises a peptide sequence Z.sup.1 and a group such that CO has one end connected to the aromatic nucleus and CO-AA is a radical derived fropm an amino acid having a specificity with respect to the protease to be inhibited.
    Type: Grant
    Filed: June 1, 1990
    Date of Patent: August 11, 1992
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Michel Wakselman, Jean-Paul Mazaleyrate, Michele Reboud-Ravaux
  • Method of fractionating plasma proteins
    Patent number: 5138034
    Abstract: A method of fractionating plasma protein which comprises treating a plasma protein-containing material in the following sequence of steps, provided that steps (ii) through (v) may be performed in an optional order: (i) freeze-thaw treatment, (ii) treatment at 5 to 10% ethanol concentration, (iii) treatment with an anion exchanger, (iv) affinity chromatography with immobilized lysine, (v) affinity chromatography with immobilized heparin, (vi) treatment at 18 to 30% ethanol concentration, (vii) treatment at 35 to 45% ethanol concentration.
    Type: Grant
    Filed: June 14, 1990
    Date of Patent: August 11, 1992
    Assignee: The Green Cross Corporation
    Inventors: Yahiro Uemura, Kazuo Takechi, Kenji Tanaka
  • Nisin compositions for use as enhanced, broad range bactericides
    Patent number: 5135910
    Abstract: Bacteriocin compositions comprising lanthionine containing bacteriocins and non-bactericidal agents. When the bacteriocin compositions are combined with a suitable carrier with each component present in sufficient quantities such that the composition is effective against Gram negative bacteria in addition to Gram positive bacteria, they become enhanced, rapid acting, broad range bactericides suitable for a variety of applications.
    Type: Grant
    Filed: February 11, 1991
    Date of Patent: August 4, 1992
    Assignee: The Public Health Research Institute of the City of New York
    Inventors: Peter Blackburn, June Polak, Sara-Ann Gusik, Stephen D. Rubino
  • Method for the treatment of grafts prior to transplantation using TGF-.beta .
    Patent number: 5135915
    Abstract: A method is provided for the treatment of grafts such as tissue or organs prior to transplantation into a suitable host. The grafts are incubated, coated, or perfused with TGF-.beta. for an effective time for the uptake of the agent into the grafts and induction of its biological effects. The thus-treated graft is then transplanted into a compatible host, preferably a human host.
    Type: Grant
    Filed: October 14, 1988
    Date of Patent: August 4, 1992
    Assignee: Genentech, Inc.
    Inventors: Christine W. Czarniecki, Michael A. Palladino, Eli Shefter
  • Process for removing toxins from protein solutions
    Patent number: 5136026
    Abstract: A process for removing toxins from solutions of proteins, in which an aqueous solution of a protein which contains a buffer substance, a chelating agent and a detergent is subjected to an ion exchange chromatography, is described.
    Type: Grant
    Filed: April 9, 1991
    Date of Patent: August 4, 1992
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Jurgen Romisch, Norbert Heimburger
  • Method to purify basic fibroblast growth factor
    Patent number: 5136025
    Abstract: This invention relates to a method of isolating and purifying proteins such as fibroblast growth factor using metal chelate affinity column chromatography and without the use of heparin. Also disclosed is a method of recovering bFGF multimers and purifying bFGF using metal chelate affinity column chromatography in the absence of heparin.
    Type: Grant
    Filed: April 4, 1990
    Date of Patent: August 4, 1992
    Assignee: California Biotechnology Inc.
    Inventors: Trina A. Scheuermann, S. Joseph Tarnowski, Stewart A. Thompson, Kate B. Silverness
  • Natriuretic peptides from the pituitary prohormone proopiomelanocortin
    Patent number: 5135912
    Abstract: Novel peptides having substantially the amino acid sequence:X-Gly-Asn-Gly-Asp-Glu-Gln-Pro-Leu-Thr-Y,where X is H, a single amino acid or a short-chain peptide and Y is OH, NH.sub.2, a single aminoacid or a short-chain peptide. These peptides have natriuretic and diuretic activity.
    Type: Grant
    Filed: May 27, 1988
    Date of Patent: August 4, 1992
    Assignee: Tosoh Corporation
    Inventors: Eckhart Wiedemann, Ding Chang
  • Thin film magnetic recording medium with controlled grain morphology and topology
    Patent number: 5134038
    Abstract: A magnetic storage medium is composed of a non-wettable substrate upon which a transient liquid metal layer is deposited and maintained as a distribution of discontinuous liquid features. A magnetic film layer is deposited on the transient liquid metal layer resulting in a reaction of the liquid metal with the magnetic film. The topology of the magnetic film is controllable by adjusting the thickness of the transient liquid metal layer.
    Type: Grant
    Filed: September 4, 1991
    Date of Patent: July 28, 1992
    Assignee: International Business Machines Corporation
    Inventors: Robert J. Baseman, Christopher V. Jahnes, Igor Y. Khandros, Seyyed M. T. Mirzamaani, Michael A. Russak
  • Nerve growth factor peptides
    Patent number: 5134121
    Abstract: The present invention provides both agonist and antagonist nerve growth factor peptides. The NGF blocking peptides can be used to inhibit the expression of mRNA and their encoded proteins whose expression is stimulated by NGF, such as .beta.-protein precursor and prion proteins, which proteins or their products are associated with neurodegenerative disorders, whereas the NGF agonist peptides can be used to treat neoplastic disorders such as neuroblastomas.
    Type: Grant
    Filed: January 14, 1991
    Date of Patent: July 28, 1992
    Assignee: Regents of the University of California
    Inventors: William C. Mobley, Frank M. Longo, James C. Kauer
  • Substantially flat surfaced vinyl polymer emulsion particles having a concavity and process for preparing them
    Patent number: 5132159
    Abstract: Substantially flat surfaced emulsion particles polymerized vinyl monomer, having a concavity in at least one of the flat surfaces, a diameter D of from 0.1 to 5.0 .mu.m, and a particle diameter thickness d ratio (d/D) of 1.2 to 5.0, prepared by the step of (1) aqueous emulsion polymerizing a first vinyl monomer or mixture of monomers (a) to form vinyl polymer seed particles; and (2) aqueous emulsion polymerizing a second vinyl monomer or mixture of monomers (b) in the presence of the vinyl polymer seed particles and a non-aqueous organic solvent having a surface tension to water at 20.degree. C. of 48 dyne/cm or more, in a weight ratio of monomer (a) to monomer (b) of 0.5/99.5 to 50/50; and are useful in high performance recording material, paint compositions and paper coating compositions.
    Type: Grant
    Filed: April 12, 1990
    Date of Patent: July 21, 1992
    Inventors: Futoshi Hoshino, Makoto Nakano, Takeshi Yanagihara
  • Method for controlling Salmonella enteritidis in poultry
    Patent number: 5132288
    Abstract: In vitro results indicate that trimethoprim may be ineffective against S. enteritides. However, in vivo results show that trimethoprim alone and in combination with polymyxin B sulfate is effective on S. enteritidis infections in poultry.
    Type: Grant
    Filed: April 27, 1990
    Date of Patent: July 21, 1992
    Assignee: Michael Foods, Inc.
    Inventors: Eric A. Johnson, Michael C. Goodnough
  • Peptides containing a (1-amino-2-hydroxy-2-heterocyclic)ethyl moiety
    Patent number: 5132400
    Abstract: The present invention provides novel peptides of the formula X-A.sub.6 -B.sub.7 -C.sub.8 -D.sub.9 -E.sub.10 -F.sub.11 containing a novel (1-amino-2-hydroxy-2-heterocyclic) ethyl moiety of the formula XL.sub.2c at the E.sub.10 -F.sub.11 -position, X is a terminal group, and the remaining variables are amino acid residues. The present invention also provides novel intermediate compounds. These peptides are useful as renin inhibitors and as inhibitors of retroviral proteases. Renin inhibitors are useful for the diagnosis and control of renin-dependent hyperaldosterism, other renin-dependent cardiovascular disorders and ocular disorders. Inhibitors of retroviral proteases, such as the HIV-I protease, are useful for treating diseases caused by retroviruses, such as human acquired immunodificiency disease syndrome (AIDS).
    Type: Grant
    Filed: April 20, 1990
    Date of Patent: July 21, 1992
    Assignee: The Upjohn Company
    Inventors: Ronald B. Gammill, Tomi K. Sawyer